Announcement • Aug 01
XORTX Therapeutics Inc. Announces Resignation of Anthony Giovinazzo from Director Role XORTX Therapeutics Inc. announced that Anthony Giovinazzo stepped down from the board of directors for personal reasons and to pursue other interests. Anthony Giovinazzo served as chairman of the board during the past several years. Anthony’s contribution to XORTX spanned leadership and ethics of the highest standards as Board chairman, and on key committees. Announcement • Jul 29
Xortx Therapeutics Inc. Announces Appointment of Depesh Narotam to Board of Directors as an Independent Director, Effective July 27, 2026 XORTX Therapeutics Inc. announce the appointment of Depesh Narotam to the board of directors as an independent director. Depesh Narotam has been in the financial services industry for over 20 years. He has developed considerable expertise in debt financing, delivering strategic lending solutions to a diverse client base. Over the course of his career Depesh has developed a comprehensive understanding of various sectors specifically the real estate lending landscape where he has been responsible for market expansion and strategic partnerships to those that have benefited from enhanced market presence and long term performance. Mr. Narotam, age 43, was appointed as a director of the Company effective July 27, 2026. The board of directors has determined that Mr. Narotam is an independent director under applicable Nasdaq listing standards and Canadian securities laws. Mr. Narotam has also been appointed to serve as a member of the Compensation, Governance and Nominating Committee of the board of directors. Mr. Narotam is a resident of British Columbia, Canada and has served as a Mortgage Development Manager since December 2020 at Vancity, Canada's largest community-based credit union and a member-owned financial co-operative. Prior to joining Vancity, Mr. Narotam spent 16 years with Westminster Savings Credit Union (now Prospera Credit Union) where he held various positions in financial services including Mortgage Specialist and Business Development Manager. Announcement • Jun 15
XORTX Therapeutics Inc. Announces Appointment of Mika Grasso to Co-CEO XORTX Therapeutics Inc. had appointed Mika Grasso as co-CEO responsible for finance and public markets. Mr. Grasso, age 28, has served as a director of the Company since March 24, 2026. Mr. Grasso has served as an Investment Manager at a family office, where he has been responsible for sourcing and evaluating the fund’s direct investment and co-investment efforts. Previously, Mr. Grasso served as a Finance Associate at Zions Capital Markets from November 2023 until March 2025, as an Investment Banking Associate at Paulson Investment Company from February 2022 until November 2023, as an Analyst at Goldman Sachs from August 2021 to February 2022, and as an Analyst on the Real Assets Team at Power Systems Management from May 2020 to August 2021. Mr. Grasso received his MS in Finance, with a concentration in Investment Management, and his BS in Business Administration from the Leeds School of Business at the University of Colorado Boulder. 
